Gland Pharma Limited has recently informed exchagnes that the Agence nationale de sécurité du médicament et des produits de santé (ANSM), France, conducted a Good Manufacturing Practices (GMP) inspection at Cenexi’s Fontenay Manufacturing Facility, a key subsidiary of Gland Pharma. The inspection took place from December 9 to December 19, 2024.
On December 24, 2024, the facility received official notification highlighting 10 observations. Cenexi is committed to addressing these points in close collaboration with the ANSM and will provide updates as progress is made.
In the meantime, on December 24, Gland Pharma shares closed at ₹1,780.00, marking a modest rise from the opening price of ₹1,774.05. The stock reached an intraday high of ₹1,807.85 and a low of ₹1,754.60. Over the past year, the 52-week high stood at ₹2,220.95, while the 52-week low was ₹1,585.70.
